Bortezomib D-Mannitol
A formulation of bortezomib, a proteasome inhibitor used to treat multiple myeloma and certain types of mantle cell lymphoma, lyophilized with d-mannitol for stability. It disrupts protein degradation pathways in cancer cells, triggering cell death. Side effects include peripheral neuropathy, low blood counts, and fatigue.
분자량
530.4000 g/mol
TPSA
183.00 Ų
작용 기전
Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.
2D 구조
Cite this structure
Embed this structure
SMILES
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1O[C@H]([C@H](O)CO)[C@@H]([C@H](O)CO)O1
InChI
InChI=1S/C25H35BN4O8/c1-15(2)10-21(26-37-22(19(33)13-31)23(38-26)20(34)14-32)30-24(35)17(11-16-6-4-3-5-7-16)29-25(36)18-12-27-8-9-28-18/h3-9,12,15,17,19-23,31-34H,10-11,13-14H2,1-2H3,(H,29,36)(H,30,35)/t17-,19+,20+,21-,22+,23+/m0/s1
Molecular Formula
C25H35BN4O8
HBD / HBA
6 / 10
회전 가능 결합
13
무거운 원자
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
A formulation of bortezomib, a proteasome inhibitor used to treat multiple myeloma and certain types of mantle cell lymphoma, lyophilized with d-mannitol for stability. It disrupts protein degradation pathways in cancer cells, triggering cell death. Side effects include peripheral neuropathy, low blood counts, and fatigue.
Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.
Yes, Bortezomib D-Mannitol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315122. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 12990536. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bortezomib-d-mannitol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bortezomib-d-mannitol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bortezomib-d-mannitol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bortezomib-d-mannitol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bortezomib-d-mannitol"></drugfyi-drug>